RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
about
Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-548an on exposure to influenza A virussiRNA Versus miRNA as Therapeutics for Gene SilencingManagement of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignanciesInduction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine designFourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirussiRNA Delivery from an Injectable Scaffold for Wound TherapyDelivery of RNAi Therapeutics to the Airways-From Bench to BedsidePreclinical and clinical development of siRNA-based therapeuticsTechnologies for controlled, local delivery of siRNAProgress toward in vivo use of siRNAs-IIAerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery SystemsMicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expressionRespiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infectionChallenges and opportunities in developing respiratory syncytial virus therapeuticsOverview of the 3rd isirv-Antiviral Group Conference--advances in clinical managementAdvances in antivirals for non-influenza respiratory virus infections.Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium.Update in respiratory infections 2011.Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.Clinical review: gene-based therapies for ALI/ARDS: where are we now?Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsRNA interference approaches for treatment of HIV-1 infectionRespiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trialsAn anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.Current progress of siRNA/shRNA therapeutics in clinical trials.Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery SystemsTarget mRNA inhibition by oligonucleotide drugs in man.Management of respiratory viral infections in hematopoietic cell transplant recipients.Symptomatic Respiratory Virus Infection and Chronic Lung Allograft DysfunctionPharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic FibrosisHow I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationEfficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA.RNAi Therapeutic Platforms for Lung Diseases.Targeting RSV with vaccines and small molecule drugs.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo.Lung transplantation: a treatment option in end-stage lung disease.Practical guidelines: lung transplantation in patients with cystic fibrosis.A review of palivizumab and emerging therapies for respiratory syncytial virus.
P2860
Q23921526-5BFC8589-896F-4FAA-BF45-293DD8C8D266Q26786876-F1007DBA-9A1A-4E59-B9BB-1C3AA6ECDF1BQ26853131-C9FE771E-C1CD-4929-845B-3C5DB438522BQ27021304-DFFAA1E2-0E03-4A5F-91ED-2690BA25D76CQ27021622-EB602CD9-3FE8-40D2-BF97-46F49C0BF5D5Q27026234-C50E9B58-BBB9-4E92-91AD-077048397EFBQ28067306-A5970BF1-DD9E-4AB6-8970-A550065525B1Q28085290-7282A0C3-F34A-4483-9D68-B4A20C363EE1Q28087657-12D6861D-AA24-4507-A334-C3C97AC355E7Q28255877-907107B1-DB5D-4B64-9753-67F5CCE3CA42Q28392004-20FE0D77-BF39-42A6-9764-4ADB989C72ACQ28395684-31155656-E1C0-4BBA-8F0C-5BB6EF804C2CQ28481271-EF177A46-7B7A-483D-A794-B01096528458Q30300567-97363E0D-255F-41F0-9C4E-64843AB75334Q30368680-6C812A69-78EA-4F9F-9BB0-7AF509D26F5CQ30457132-A21B1506-BF07-4136-BF31-5EDC914F1A0EQ33732559-300A0965-E7ED-4805-AFCC-7160D2089EF2Q33738738-41732A8F-C569-49DA-B4F6-3BB6B0E1FD10Q33840252-B1D8914D-21C2-4B29-BD2C-35D638E832EBQ35558172-90C15D52-12A8-479F-8E8F-CEB60526D22DQ35566601-672856F5-4D4B-4B48-99C1-95DEE119B3BBQ35652119-084BB1F4-5C70-4E98-9A36-3202D2F47E1CQ35761061-5010D810-A774-4004-BB20-D47D97E9F55BQ35893983-ECF7C6FE-BEBE-4810-91B5-8ABB2EE9D371Q36071638-1B429052-4BC2-4426-B9FF-5F8388E38C23Q36086410-E01E5755-808D-40D3-BBC5-802508B54DA9Q36341433-346AE7DA-E9EA-4B1F-BC61-7299B51EFFB6Q36435109-A8C744B8-E2D2-4666-93BE-C33051DF0B28Q36439896-77ACDEC2-5AFD-4886-A45D-48D600F18F9EQ36446117-A1654B15-CB04-4772-8FCD-60D7AADB66D5Q36587576-4F422515-B3D8-4389-900B-CDC7DA95C33CQ36965855-7BDCA34B-8AC4-4C72-8911-E537E9CCE6E5Q36968187-2C6DAE14-78DC-4038-A0BE-8FE7FC51CD38Q37277373-257B622D-53B6-482A-91F2-1631D9AB2E5EQ37328584-5DA2FF83-61D1-48E0-92A8-56CD788FB531Q37412509-D5ED12D7-FB11-4656-A862-7C060DF2A483Q37633993-444973D7-7E90-40EA-8C12-00B5BB440A78Q37642300-FC6184A8-1F02-4DFE-ABD4-14A34B2112A5Q37706330-15C4E1AA-8F83-4C2B-A08E-186447BC348DQ37914882-6A64ADED-8455-48C4-88C4-B1F6F71E2572
P2860
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
RNA interference therapy in lu ...... h respiratory syncytial virus.
@en
RNA interference therapy in lu ...... h respiratory syncytial virus.
@nl
type
label
RNA interference therapy in lu ...... h respiratory syncytial virus.
@en
RNA interference therapy in lu ...... h respiratory syncytial virus.
@nl
prefLabel
RNA interference therapy in lu ...... h respiratory syncytial virus.
@en
RNA interference therapy in lu ...... h respiratory syncytial virus.
@nl
P2093
P2860
P1476
RNA interference therapy in lu ...... h respiratory syncytial virus.
@en
P2093
Akshay Vaishnaw
Allan R Glanville
Atul Humar
Gary Albert
Jared A Gollob
Jeffrey Cehelsky
Jens Gottlieb
John Devincenzo
Marie Budev
Mark Rolfe
P2860
P304
P356
10.1164/RCCM.201003-0422OC
P407
P577
2010-09-17T00:00:00Z